Last reviewed · How we verify
NCT06246331
Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection
trial in Reversal of Neuromuscular Blockade in 1,500 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Hanlim Pharm. Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 21 July 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Conditions studied
- Reversal of Neuromuscular Blockade — all drugs for Reversal of Neuromuscular Blockade →
Sponsor
Hanlim Pharm. Co., Ltd. — full company profile →
Who can join
19 and older, any sex, with Reversal of Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluate clinical efficacy and safety in adult patients administered BriTurn injection or BrisTurn Prefilled injection for reversal of neuromuscular blockade induced by Rocuronium or Vecuronium.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06246331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Reversal of Neuromuscular Blockade
Currently open trials in the same condition.
- NCT07044180 — Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia · Phase 4 · active not recruiting
Other Hanlim Pharm. Co., Ltd. trials
Trials by the same sponsor.
- NCT06475872 — Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuva · Phase 1 · completed
- NCT06642987 — Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adu · Phase 1 · completed
- NCT06130124 — S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement · unknown
- NCT05358080 — Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy · Phase 4 · unknown
- NCT06191614 — DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06246331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hanlim Pharm. Co., Ltd.
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing